Akebia Therapeutics Inc. (AKBA) 22.39 $AKBA
Akebia to Present at the Annual UBS Global Healthcare Conference
Business Wire - Mon May 12, 8:31AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present at the annual UBS Global Healthcare Conference on Monday, May 19, at 2:30 p.m. Eastern Time. The conference will take place at The Sheraton Hotel in New York City.
Akebia Announces First Quarter 2014 Financial Results and Recent Corporate Highlights
Business Wire - Mon May 12, 6:01AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced financial results for the first quarter ended March 31, 2014.
Global Colitis Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 32 Drug Profiles
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zwv5t/colitis) has announced the addition of the "Colitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Colitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Colitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Colitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Colitis - Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - BioLineRx, Ltd. - Pfizer Inc. - Idera Pharmaceuticals, Inc. - Lpath, Inc. - Protalix BioTherapeutics, Inc. - Galapagos NV - Akebia Therapeutics, Inc. - NasVax Ltd. - Lycera Corp. - Zyngenia, Inc. - N30 Pharmaceuticals - Cognosci, Inc. - Atlantic Healthcare Limited - CellAct Pharma GmbH - Ajinomoto Pharmaceuticals Co., Ltd. Drug Profiles - LT-1009 - PF-06425090 - IMO-3100 - BL-5040 - VGX-1027 - N-6022 - GLPG-0634 - COG-112 - Anti-CD3 Oral Immunotherapy - etanercept biosimilar - N-6547 - BRA-101 - Bioenergetics Program - ARA-290 - CAP-2.1 - CAP-2.2 - Clostridium difficile Vaccine - Cathelicidin - IP-1510 - Helminth-Derived Peptides - Drugs to Inhibit Panx1 for Colitis - Recombinant Cholera Toxin-B - Bi-Specific Anti-TNFalpha/Ang2 Zybody - auranofin - NK-007 - Treg Cells to Inhibit TCR Antagonist for Colitis - Vaccine for Colitis and Respiratory Tract Inflammatory Disorders - APY-0201 - IL-23 P19 Vaccine - AKB-6899 For more information visit http://www.researchandmarkets.com/research/3zwv5t/colitis
Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate Updates - Analyst Notes on Insmed, Akebia, Retrophin, Agios and Spectranetics
PR Newswire - Wed Apr 23, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Akebia Therapeutics, Inc. (NASDAQ: AKBA), Retrophin, Inc. (NASDAQ: RTRX), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and The Spectranetics Corporation (NASDAQ: SPNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1455-100free.
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Fri Apr 18, 11:54AM CDT
Many Americans didn't particularly enjoy this week as the dreaded April 15 federal tax deadline arrived. However, some health-care investors had reason to celebrate even if they had to pay up to Uncle Sam. Three stocks, in particular, enjoyed huge...
Technical Data on Top Gainers -- Research on Aruba Networks, Akebia Therapeutics, bebe stores, and Allscripts Healthcare Solutions
PR Newswire - Tue Apr 15, 11:03AM CDT
The US markets saw a positive sentiment on Monday, April 14, 2014, with the NASDAQ Composite closing at 4,022.69, up 0.57%, the Dow Jones Industrial Average ending the session at 16173.24, up 0.91%, and the S&P 500 gained 0.82% to finish the trading session at 1830.61. The gains were broad based as all the ten sectors finished on a positive note. A number of stocks saw large movements, including Aruba Networks Inc. (NASDAQ: ARUN), Akebia Therapeutics Inc. (NASDAQ: AKBA), bebe stores inc. (NASDAQ: BEBE) and Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX). Free technical research on ARUN, AKBA, BEBE and MDRX can be downloaded upon signing up at:
Akebia Therapeutics Announces Completion of Enrollment in its Phase 2b Clinical Study of AKB-6548
Business Wire - Tue Apr 15, 8:20AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.
Why Halcon Resources, Bebe Stores, and Akebia Therapeutics Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Apr 14, 7:05PM CDT
Investors came back from the weekend refreshed after last week's substantial losses, and the stock market bounced back to produce fairly strong gains Monday. Government data showed a sharp rise in retail sales in the U.S. last month, and that...
Why Akebia Therapeutics (AKBA) Stock Soared Today
at The Street - Mon Apr 14, 3:21PM CDT
Akebia Therapeutics (AKBA) soared more than 25% on Monday on high volume after UBS initiated coverage on the biopharmaceutical company with a "buy" rating and $28 price target.
Today’s Top Biotech Stories: Lexicon, Alimera, and Akebia
Leo Sun, The Motley Fool - Motley Fool - Mon Apr 14, 8:13AM CDT
Let's take a quick look at three biotech stocks -- Lexicon Pharmaceuticals , Alimera Sciences , and Akebia Therapeutics -- which could all be lifted by positive headlines this Monday morning . Lexicon soars on positive top-line results for...
Akebia Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Wed Mar 26, 7:02AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the closing of its initial public offering of 6,762,000 shares of common stock at an initial public offering price of $17.00 per share. This includes the exercise in full by the underwriters of their option to purchase 879,647 shares of common stock. The aggregate net proceeds to Akebia, after underwriting discounts and commissions and estimated offering expenses, are approximately $106.9 million. All of the shares of common stock were offered by Akebia.
3 IPOs launched, more on Fri.
at Investor's Business Daily - Thu Mar 20, 5:47PM CDT
Shares of Akebia Therapeutics (AKBA), a biopharmaceutical company focused on therapies for kidney disease, priced at 17 and opened at 22.90. Shares ended the day at 26.69. Q2 Holdings (QTWO), which provides online banking services, priced at 13 and...
IPO Sizzle Continues With A10 Networks Set For Friday
at Investor's Business Daily - Thu Mar 20, 1:03PM CDT
Three IPOs launched Thursday, continuing a hot streak that will carry into Friday when A10 Networks (ATEN) is set to debut. A top performer Thursday was Akebia Therapeutics (AKBA), a biopharmaceutical company focused on therapies for patients with...
Akebia and MediWound rise as health IPOs continue
AP - Thu Mar 20, 11:11AM CDT
NEW YORK (AP) — Drug developer Akebia Therapeutics and burn treatment maker MediWound both went public Thursday as the tide of health care IPOs continued to rise.
Akebia Therapeutics Announces Pricing of Initial Public Offering
Business Wire - Thu Mar 20, 7:01AM CDT
Akebia Therapeutics, Inc. today announced the pricing of its initial public offering of 5,882,353 shares of common stock at an initial public offering price of $17.00 per share. In addition, Akebia has granted the underwriters a 30-day over-allotment option to purchase up to an additional 879,647 shares of common stock at the initial public offering price. The shares of Akebia's common stock are expected to begin trading on the NASDAQ Global Market on March 20, 2014 under the ticker symbol "AKBA." The offering is expected to close on March 25, 2014, subject to customary closing conditions.
Paylocity IPO Pops, Maintaining New-Issue Enthusiasm
at Investor's Business Daily - Wed Mar 19, 11:12AM CDT
The Paylocity Holding (PCTY) IPO jumped Wednesday, setting the stage for nine more IPOs this week, as new issues remain hot. Paylocity priced at 17 on Tuesday evening, above its expected range, and opened at 31 on the Nasdaq Wednesday morning. In...
Akebia Therapeutics Files Registration Statement for Proposed Initial Public Offering
Business Wire - Tue Feb 18, 9:00AM CST
Akebia Therapeutics, a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the filing of a Registration Statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares to be sold in the proposed offering will be offered by Akebia Therapeutics. Akebia Therapeutics has applied for a listing of its common stock on The NASDAQ Stock Market under the symbol "AKBA". The number of shares to be offered and the price range for the offering have not yet been determined.
Akebia Therapeutics Appoints Michael Wyzga to its Board of Directors
Business Wire - Tue Feb 18, 9:00AM CST
Akebia Therapeutics, a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the appointment of Michael S. Wyzga as an independent member to the company's Board of Directors. Mr. Wyzga will serve as the Chairman of Akebia's Audit Committee.
Akebia to Present at the Annual UBS Global Healthcare Conference
Business Wire - Mon May 12, 8:31AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present at the annual UBS Global Healthcare Conference on Monday, May 19, at 2:30 p.m. Eastern Time. The conference will take place at The Sheraton Hotel in New York City.
Akebia Announces First Quarter 2014 Financial Results and Recent Corporate Highlights
Business Wire - Mon May 12, 6:01AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced financial results for the first quarter ended March 31, 2014.
Global Colitis Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 32 Drug Profiles
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zwv5t/colitis) has announced the addition of the "Colitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Colitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Colitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Colitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Colitis - Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - BioLineRx, Ltd. - Pfizer Inc. - Idera Pharmaceuticals, Inc. - Lpath, Inc. - Protalix BioTherapeutics, Inc. - Galapagos NV - Akebia Therapeutics, Inc. - NasVax Ltd. - Lycera Corp. - Zyngenia, Inc. - N30 Pharmaceuticals - Cognosci, Inc. - Atlantic Healthcare Limited - CellAct Pharma GmbH - Ajinomoto Pharmaceuticals Co., Ltd. Drug Profiles - LT-1009 - PF-06425090 - IMO-3100 - BL-5040 - VGX-1027 - N-6022 - GLPG-0634 - COG-112 - Anti-CD3 Oral Immunotherapy - etanercept biosimilar - N-6547 - BRA-101 - Bioenergetics Program - ARA-290 - CAP-2.1 - CAP-2.2 - Clostridium difficile Vaccine - Cathelicidin - IP-1510 - Helminth-Derived Peptides - Drugs to Inhibit Panx1 for Colitis - Recombinant Cholera Toxin-B - Bi-Specific Anti-TNFalpha/Ang2 Zybody - auranofin - NK-007 - Treg Cells to Inhibit TCR Antagonist for Colitis - Vaccine for Colitis and Respiratory Tract Inflammatory Disorders - APY-0201 - IL-23 P19 Vaccine - AKB-6899 For more information visit http://www.researchandmarkets.com/research/3zwv5t/colitis
Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate Updates - Analyst Notes on Insmed, Akebia, Retrophin, Agios and Spectranetics
PR Newswire - Wed Apr 23, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Akebia Therapeutics, Inc. (NASDAQ: AKBA), Retrophin, Inc. (NASDAQ: RTRX), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and The Spectranetics Corporation (NASDAQ: SPNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1455-100free.
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Fri Apr 18, 11:54AM CDT
Many Americans didn't particularly enjoy this week as the dreaded April 15 federal tax deadline arrived. However, some health-care investors had reason to celebrate even if they had to pay up to Uncle Sam. Three stocks, in particular, enjoyed huge...
Technical Data on Top Gainers -- Research on Aruba Networks, Akebia Therapeutics, bebe stores, and Allscripts Healthcare Solutions
PR Newswire - Tue Apr 15, 11:03AM CDT
The US markets saw a positive sentiment on Monday, April 14, 2014, with the NASDAQ Composite closing at 4,022.69, up 0.57%, the Dow Jones Industrial Average ending the session at 16173.24, up 0.91%, and the S&P 500 gained 0.82% to finish the trading session at 1830.61. The gains were broad based as all the ten sectors finished on a positive note. A number of stocks saw large movements, including Aruba Networks Inc. (NASDAQ: ARUN), Akebia Therapeutics Inc. (NASDAQ: AKBA), bebe stores inc. (NASDAQ: BEBE) and Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX). Free technical research on ARUN, AKBA, BEBE and MDRX can be downloaded upon signing up at:
Akebia Therapeutics Announces Completion of Enrollment in its Phase 2b Clinical Study of AKB-6548
Business Wire - Tue Apr 15, 8:20AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.
Why Halcon Resources, Bebe Stores, and Akebia Therapeutics Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Apr 14, 7:05PM CDT
Investors came back from the weekend refreshed after last week's substantial losses, and the stock market bounced back to produce fairly strong gains Monday. Government data showed a sharp rise in retail sales in the U.S. last month, and that...
Why Akebia Therapeutics (AKBA) Stock Soared Today
at The Street - Mon Apr 14, 3:21PM CDT
Akebia Therapeutics (AKBA) soared more than 25% on Monday on high volume after UBS initiated coverage on the biopharmaceutical company with a "buy" rating and $28 price target.
Today’s Top Biotech Stories: Lexicon, Alimera, and Akebia
Leo Sun, The Motley Fool - Motley Fool - Mon Apr 14, 8:13AM CDT
Let's take a quick look at three biotech stocks -- Lexicon Pharmaceuticals , Alimera Sciences , and Akebia Therapeutics -- which could all be lifted by positive headlines this Monday morning . Lexicon soars on positive top-line results for...
Akebia Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Wed Mar 26, 7:02AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the closing of its initial public offering of 6,762,000 shares of common stock at an initial public offering price of $17.00 per share. This includes the exercise in full by the underwriters of their option to purchase 879,647 shares of common stock. The aggregate net proceeds to Akebia, after underwriting discounts and commissions and estimated offering expenses, are approximately $106.9 million. All of the shares of common stock were offered by Akebia.
3 IPOs launched, more on Fri.
at Investor's Business Daily - Thu Mar 20, 5:47PM CDT
Shares of Akebia Therapeutics (AKBA), a biopharmaceutical company focused on therapies for kidney disease, priced at 17 and opened at 22.90. Shares ended the day at 26.69. Q2 Holdings (QTWO), which provides online banking services, priced at 13 and...
IPO Sizzle Continues With A10 Networks Set For Friday
at Investor's Business Daily - Thu Mar 20, 1:03PM CDT
Three IPOs launched Thursday, continuing a hot streak that will carry into Friday when A10 Networks (ATEN) is set to debut. A top performer Thursday was Akebia Therapeutics (AKBA), a biopharmaceutical company focused on therapies for patients with...
Akebia and MediWound rise as health IPOs continue
AP - Thu Mar 20, 11:11AM CDT
NEW YORK (AP) — Drug developer Akebia Therapeutics and burn treatment maker MediWound both went public Thursday as the tide of health care IPOs continued to rise.
Akebia Therapeutics Announces Pricing of Initial Public Offering
Business Wire - Thu Mar 20, 7:01AM CDT
Akebia Therapeutics, Inc. today announced the pricing of its initial public offering of 5,882,353 shares of common stock at an initial public offering price of $17.00 per share. In addition, Akebia has granted the underwriters a 30-day over-allotment option to purchase up to an additional 879,647 shares of common stock at the initial public offering price. The shares of Akebia's common stock are expected to begin trading on the NASDAQ Global Market on March 20, 2014 under the ticker symbol "AKBA." The offering is expected to close on March 25, 2014, subject to customary closing conditions.
Paylocity IPO Pops, Maintaining New-Issue Enthusiasm
at Investor's Business Daily - Wed Mar 19, 11:12AM CDT
The Paylocity Holding (PCTY) IPO jumped Wednesday, setting the stage for nine more IPOs this week, as new issues remain hot. Paylocity priced at 17 on Tuesday evening, above its expected range, and opened at 31 on the Nasdaq Wednesday morning. In...
Akebia Therapeutics Files Registration Statement for Proposed Initial Public Offering
Business Wire - Tue Feb 18, 9:00AM CST
Akebia Therapeutics, a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the filing of a Registration Statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares to be sold in the proposed offering will be offered by Akebia Therapeutics. Akebia Therapeutics has applied for a listing of its common stock on The NASDAQ Stock Market under the symbol "AKBA". The number of shares to be offered and the price range for the offering have not yet been determined.
Akebia Therapeutics Appoints Michael Wyzga to its Board of Directors
Business Wire - Tue Feb 18, 9:00AM CST
Akebia Therapeutics, a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced the appointment of Michael S. Wyzga as an independent member to the company's Board of Directors. Mr. Wyzga will serve as the Chairman of Akebia's Audit Committee.
